Basit öğe kaydını göster

dc.contributor.authorSatana, Dilek
dc.contributor.authorCoban, Ahmet Yilmaz
dc.contributor.authorUzun, Meltem
dc.date.accessioned2020-06-21T14:46:50Z
dc.date.available2020-06-21T14:46:50Z
dc.date.issued2010
dc.identifier.issn0095-1137
dc.identifier.issn1098-660X
dc.identifier.urihttps://doi.org/10.1128/JCM.00688-10
dc.identifier.urihttps://hdl.handle.net/20.500.12712/17676
dc.descriptionSatana, Dilek/0000-0002-8827-1504;en_US
dc.descriptionWOS: 000283588500075en_US
dc.descriptionPubMed: 20826642en_US
dc.description.abstractIn this study, the susceptibilities of 35 multidrug-resistant (MDR) Mycobacterium tuberculosis clinical isolates to second-line drugs, including kanamycin (KM), rifabutin (RBU), ofloxacin (OFX), p-aminosalicylic acid (PAS), capreomycin (CAP), clofazimine (CFM), and ethionamide (ETH), were investigated on blood agar according to CLSI recommendations. Compared with the results of the Bactec 460 TB system, agreement was 100, 100, 97, 100, 100, 100, and 86% for KM, RBU, OFX, PAS, CAP, CFM, and ETH, respectively. Compared with the results of the proportion method, agreement was 100, 100, 97, 100, 97, 100, and 77% for KM, RBU, OFX, PAS, CAP, CFM, and ETH, respectively.en_US
dc.language.isoengen_US
dc.publisherAmer Soc Microbiologyen_US
dc.relation.isversionof10.1128/JCM.00688-10en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleTesting Susceptibility of Multidrug-Resistant Mycobacterium tuberculosis to Second-Line Drugs by Use of Blood Agaren_US
dc.typearticleen_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume48en_US
dc.identifier.issue11en_US
dc.identifier.startpage4291en_US
dc.identifier.endpage4293en_US
dc.relation.journalJournal of Clinical Microbiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster